Citius Pharmaceuticals : CTXR Factsheet

Investor Fact Sheet

Spring 2024

Nasdaq: CTXR

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company with a diversified pipeline of late- stage assets. The Company is advancing two specialty pharma products through the FDA's 505(b)(2) fast-trackapproval pathway, Mino-Lok®,Phase 3 completed; and Halo-Lido,Phase 2b completed. The Company also has a complex biological that was previously FDA-approvedand marketed, LYMPHIR™, Phase 3 completed, BLA under

FDA review. TS

DIVERSIFIED PIPELINE

MINO-LOK®

A novel first and only antibiotic lock solution to salvage catheters for patients with bloodstream infections.

• Positive Phase 2 data: strong safety and efficacy signal.
• Status: Phase 3 trialcompleted December 2023; topline results expected 1H 2024.
• Market: Catheter-related bloodstream infection (CRBSI) and central line-associated bloodstream infection (CLABSI) market total estimated at >$1.8B worldwide.
• First and only advantage: No current FDA-approved or investigational products to salvage infected CVCs.

LYMPHIR™

A purified reformulation of denileukin diftitox (ONTAK®), which was previously approved by the FDA for persistent or recurrent CTCL, and marketed from 1999 to 2014 when voluntarily removed; first commercial product in the Company's asset portfolio if FDA approved.

• Positive Phase 3 results: Outcomes consistent with data from ONTAK studies; no new safety concerns.
• Status: August 13, 2024 Prescription Drug User Fee Act (PDUFA) target action date; 2H 2024 commercialization planned, if approved.
• Market: Estimated $300-$400+M addressable U.S. market with additional growth opportunities; historically, new market entrants have expanded the size of the market.
• Market advantage: No curative therapeutics on the market. Only IL-2R targeted therapy.

HALO-LIDO

A proprietary topical cream formulation intended to provide anti-inflammatory and anesthetic relief to individuals suffering from hemorrhoids.

• Positive Phase 2b results: Meaningful reduction in symptom severity when compared to individual components alone.
• Status: Dose for Phase 3 trial selected; end of Phase 2 meeting with FDA 1H 2024.
• Market: +10M patients report symptoms of hemorrhoidal disease; 1/3 seek physician treatment.1
• First and only advantage: No FDA-approved prescription hemorrhoid products available.

INVESTMENT HIGHLIGHTS

• Diversified Portfolio of Potential First-in-Class Products. Multiple near-termcatalysts.
• Multi-BillionDollar Global Market Opportunities. Adjunctive cancer care, infectious disease, and gastrointestinal disease.
• Proven Leadership Team. Extensive pharma operational and value creation track record pre-Citius.
• Strong Financial Platform. Financial stewardship supports pipeline development and investment in long-term growth; $26.5 M invested by insiders.
• Unique Market Advantages. 505(b)(2) fast-track pathways; potential first-and-only market entrants.

BUSINESS DEVELOPMENT

CITIUS ONCOLOGY

An anticipated oncology-focused publicly traded spin-off of Citius to be formed via a planned merger with TenX Keane Acquisition (SPAC).

• Intended to unlock value of the Company's oncology business, which management believes is not currently priced into valuation.
• Facilitates greater access to capital markets for Citius Oncology.
• Citius to receive $675M in shares of Citius Oncology and retain ~90% equity.

ADDITIONAL LYMPHIR™ OPPORTUNITIES

LYMPHIR's differentiated mechanism-of-action may offer potential beyond CTCL. Two Investigator-initiated Phase 1 studies are underway:

• LYMPHIR in combination with KEYTRUDA® in patients with recurrent or metastatic solid tumors (NCT05200559) at the University of Pittsburgh.
• LYMPHIR given prior to lymphodepletion chemotherapy and FDA-approvedCAR-Ts2 for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma, who are at a high risk of failure of CAR-T therapy alone at the University of Minnesota.

CITIUS OFFICERS

Leonard Mazur	Myron Holubiak	Jamie Bartushak	Myron Czuczman, MD
CHAIRMAN & CEO,	EXECUTIVE VICE	CFO & CHIEF BUSINESS	CHIEF MEDICAL OFFICER,
CO-FOUNDER	CHAIRMAN, CO-FOUNDER	OFFICER, EVP	EVP

STOCK DATA

Share Price	52-Wk. Range	Avg. Vol.	Shares O/S	Market Cap
$0.68 (5/14/24)	$0.60 - $1.40	957K	180M	$123 M
1MAYO CLINIC Hemorrhoidal disease: Diagnosis and management
2KYMRIAH, YESCARTA, and BREYANZI
Citius Pharmaceuticals, Inc.			Investor Relations Contact
11 Commerce Drive, First Floor			IIanit Allen
Canford, NJ 07016				[phone] x113
www.citiuspharma.com				[e-mail]

Forward-Looking Statements: This fact sheet has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any other purpose. Nothing contained in this document is, or should be construed as, a recommendation, promise or representation by the Company or any director, employee, agent, or adviser of the Company. This document does not purport to be all-inclusive or to contain all of the information you may desire. The Company assumes no obligation to update any statement after the date of this document as a result of new information, subsequent events or any other circumstances. This document includes express and implied forward-looking statements regarding the current expectations, estimates, opinions and beliefs of the Company that are not historical facts. Such forward-looking statements may be identified by words such as "believes", "expects", "endeavors", "anticipates", "intends", "plans", "estimates", "projects", "should", "objective" and variations of such words and similar words. The accuracy of such statements is dependent upon future events, and involves known and unknown risks, uncertainties and other factors beyond the Company's control that may cause actual results to differ materially from what is presented herein. Investors are strongly encouraged to carefully review the Company's SEC filings for a listing of the risks that could cause actual results to differ from these forward-looking statements. Information provided in this document speaks only as of the date hereof and should not be construed as statements of facts.